CIM
BIO icon

Contravisory Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Contravisory Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,730
Closed -$421K – 377
2025
Q1 		$421K Sell
1,730
-1
-0.1% -$301 0.09% 175
2024
Q4 		$569K Buy
+1,731
New +$588K 0.12% 113
2022
Q1 		– Sell
-801
Closed -$605K – 337
2021
Q4 		$605K Buy
+801
New +$599K 0.16% 86

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Contravisory Investment Management's BIO Position: Q2 2025 in Review

Contravisory Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 1,730 shares — an estimated $421K sold.

Contravisory Investment Management first reported a position in BIO in Q4 2021 and held it in 3 quarters. The position peaked at $605K in Q4 2021. 383 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

  • Contravisory Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
  • Contravisory Investment Management sold 1,730 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $421K.
  • Contravisory Investment Management first reported a position in Bio-Rad Laboratories Class A in Q4 2021 and held it in 3 quarters.
  • Contravisory Investment Management's Bio-Rad Laboratories Class A position peaked at $605K in Q4 2021.
  • 383 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Contravisory Investment Management's 13F filing for Q2 2025, filed 10 Jul 2025.